In this special edition episode of Liver Lineup, recorded as part of HCPLive's This Year in Medicine series, hosts Nancy Reau, MD, and Kimberly Brown, MD, break down the most consequential updates of the year across primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH), highlighting data that may reshape both near-term management and longer-term treatment strategies.

Key episode timestamps:
0:00:00 – Intro
0:00:40 – Underuse of second‑line therapy in PBC
0:03:40 – Long‑term data on PPAR agonists (elafibranor, seladelpar) in PBC
0:09:35 – PSC: elafibranor (Elmwood trial) and CCL24 mAb (nabokitug)
0:15:56 – Cholestasis symptoms: fatigue and pruritus and PPAR impact
0:20:20 – Autoimmune hepatitis: limitations of current therapy; new agent